QQQ   282.69 (-0.41%)
AAPL   141.56 (-0.76%)
MSFT   245.26 (-0.86%)
META   114.65 (-0.59%)
GOOGL   93.81 (+0.11%)
AMZN   89.44 (-1.01%)
TSLA   177.03 (+2.07%)
NVDA   171.09 (-0.35%)
NIO   13.17 (-1.79%)
BABA   93.25 (-0.98%)
AMD   68.97 (-2.13%)
T   19.16 (+0.21%)
MU   54.94 (-0.47%)
CGC   3.02 (-2.27%)
F   13.19 (+0.53%)
GE   82.46 (-1.40%)
DIS   93.10 (+0.59%)
AMC   5.97 (-1.65%)
PYPL   73.79 (-0.58%)
PFE   52.41 (+1.22%)
NFLX   320.09 (+3.17%)
QQQ   282.69 (-0.41%)
AAPL   141.56 (-0.76%)
MSFT   245.26 (-0.86%)
META   114.65 (-0.59%)
GOOGL   93.81 (+0.11%)
AMZN   89.44 (-1.01%)
TSLA   177.03 (+2.07%)
NVDA   171.09 (-0.35%)
NIO   13.17 (-1.79%)
BABA   93.25 (-0.98%)
AMD   68.97 (-2.13%)
T   19.16 (+0.21%)
MU   54.94 (-0.47%)
CGC   3.02 (-2.27%)
F   13.19 (+0.53%)
GE   82.46 (-1.40%)
DIS   93.10 (+0.59%)
AMC   5.97 (-1.65%)
PYPL   73.79 (-0.58%)
PFE   52.41 (+1.22%)
NFLX   320.09 (+3.17%)
QQQ   282.69 (-0.41%)
AAPL   141.56 (-0.76%)
MSFT   245.26 (-0.86%)
META   114.65 (-0.59%)
GOOGL   93.81 (+0.11%)
AMZN   89.44 (-1.01%)
TSLA   177.03 (+2.07%)
NVDA   171.09 (-0.35%)
NIO   13.17 (-1.79%)
BABA   93.25 (-0.98%)
AMD   68.97 (-2.13%)
T   19.16 (+0.21%)
MU   54.94 (-0.47%)
CGC   3.02 (-2.27%)
F   13.19 (+0.53%)
GE   82.46 (-1.40%)
DIS   93.10 (+0.59%)
AMC   5.97 (-1.65%)
PYPL   73.79 (-0.58%)
PFE   52.41 (+1.22%)
NFLX   320.09 (+3.17%)
QQQ   282.69 (-0.41%)
AAPL   141.56 (-0.76%)
MSFT   245.26 (-0.86%)
META   114.65 (-0.59%)
GOOGL   93.81 (+0.11%)
AMZN   89.44 (-1.01%)
TSLA   177.03 (+2.07%)
NVDA   171.09 (-0.35%)
NIO   13.17 (-1.79%)
BABA   93.25 (-0.98%)
AMD   68.97 (-2.13%)
T   19.16 (+0.21%)
MU   54.94 (-0.47%)
CGC   3.02 (-2.27%)
F   13.19 (+0.53%)
GE   82.46 (-1.40%)
DIS   93.10 (+0.59%)
AMC   5.97 (-1.65%)
PYPL   73.79 (-0.58%)
PFE   52.41 (+1.22%)
NFLX   320.09 (+3.17%)
NASDAQ:AMED

Amedisys - AMED Stock Forecast, Price & News

$87.07
+0.72 (+0.83%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$85.77
$87.68
50-Day Range
$84.60
$105.34
52-Week Range
$83.00
$179.91
Volume
303,068 shs
Average Volume
343,595 shs
Market Capitalization
$2.83 billion
P/E Ratio
23.47
Dividend Yield
N/A
Price Target
$136.13

Amedisys MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
56.3% Upside
$136.13 Price Target
Short Interest
Healthy
5.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.62mentions of Amedisys in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.01%
From $4.85 to $5.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

14th out of 1,022 stocks

Home Health Care Services Industry

1st out of 9 stocks

AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Stock News Headlines

StockNews.com Upgrades Amedisys (NASDAQ:AMED) to Buy
Amedisys: No Change To Thesis, Retain Hold
Amedisys Names Scott Ginn Acting Chief Operating Officer
Amedisys reaffirms FY22 guidance
Amedisys Third Quarter 2022 Earnings: Misses Expectations
Amedisys Statement on CY 2023 Home Health Final Rule
Expert Ratings for Amedisys
6 Analysts Have This to Say About Amedisys
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
10/26/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
21,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$136.13
High Stock Price Forecast
$195.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+56.3%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

Net Income
$209.07 million
Pretax Margin
7.47%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$8.30 per share
Book Value
$29.95 per share

Miscellaneous

Free Float
31,810,000
Market Cap
$2.83 billion
Optionable
Optionable
Beta
0.94

Social Links


Key Executives

  • Christopher T. GerardChristopher T. Gerard
    President, Chief Executive Officer & Director
  • Scott G. GinnScott G. Ginn
    Chief Financial Officer & Executive Vice President
  • Michael P. NorthMichael P. North
    Chief Information Officer
  • Denise M. BohnertDenise M. Bohnert
    Chief Compliance Officer
  • Nick Muscato
    Chief Strategy Officer













AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2023?

15 brokers have issued twelve-month target prices for Amedisys' stock. Their AMED share price forecasts range from $88.00 to $195.00. On average, they expect the company's stock price to reach $136.13 in the next year. This suggests a possible upside of 56.3% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2022?

Amedisys' stock was trading at $161.88 on January 1st, 2022. Since then, AMED shares have decreased by 46.2% and is now trading at $87.07.
View the best growth stocks for 2022 here
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) posted its quarterly earnings data on Wednesday, October, 26th. The health services provider reported $1.15 earnings per share for the quarter, missing analysts' consensus estimates of $1.24 by $0.09. The health services provider had revenue of $557.99 million for the quarter, compared to the consensus estimate of $579.30 million. Amedisys had a trailing twelve-month return on equity of 16.00% and a net margin of 5.45%. Amedisys's quarterly revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.53 EPS.

How will Amedisys' stock buyback program work?

Amedisys declared that its board has approved a share buyback program on Wednesday, August 4th 2021, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY22 earnings guidance on Friday, November, 18th. The company provided earnings per share guidance of $4.82-4.93 for the period, compared to the consensus EPS estimate of $4.84. The company issued revenue guidance of $2.22-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.19%), Vanguard Group Inc. (9.36%), Riverbridge Partners LLC (5.02%), Point72 Asset Management L.P. (3.30%), Mackenzie Financial Corp (3.09%) and State Street Corp (2.68%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $87.07.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $2.83 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $3.71 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 21,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 12/9/2022 by MarketBeat.com Staff